FH

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

Retrieved on: 
Thursday, April 13, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Tissue, Precision BioSciences, Patent, Hepatitis, Central nervous system, Duchenne muscular dystrophy, Gene editing, FH, CTA, AAV, Precision, Stem cell, Novartis, Lilly, OTC, PCSK9, Liver, Genetic distance, Entrepreneurship, IND, Family, Safety, Vaccine

16/606,856, titled “Engineered meganucleases specific for recognition sequences in the PCSK9 gene.” Corresponding international applications in this family have also been allowed in Europe, Australia, Mexico, Japan, and Israel since October 2022.

Key Points: 
  • 16/606,856, titled “Engineered meganucleases specific for recognition sequences in the PCSK9 gene.” Corresponding international applications in this family have also been allowed in Europe, Australia, Mexico, Japan, and Israel since October 2022.
  • Once issued, patents arising from these international applications will have standard expiration dates in October 2038, and the U.S. patent arising from the ‘856 application will have a standard expiration date in August 2040.
  • The allowed composition of matter claims in these U.S. and international applications encompass a PCSK9-specific ARCUS nuclease.
  • In addition, iECURE is targeting to file a CTA and/or IND for a product incorporating the Precision PCSK9 nuclease for ornithine transcarbamylase (OTC) deficiency in the second half of 2023.

QNET's Swiss Luxury Brand, Bernhard H. Mayer, Launches Limited Edition Mecanique Watch

Retrieved on: 
Friday, April 7, 2023
Mechanics, Mayers, Federation of the Swiss Watch Industry, FH, QNET, ETA, Gold standard, Black Forest, Federation, Gold, Collection, Family, Musique Mecanique, Iron ore, Fashion design, Clockmaker, Jewellery

HONG KONG, April 7, 2023 /PRNewswire/ -- Bernhard H. Mayer , QNET 's Swiss luxury brand, is proud to launch a new timepiece under its Mecanique Collection , the watchmaker's range of prestigious and distinct self-winding watches.

Key Points: 
  • HONG KONG, April 7, 2023 /PRNewswire/ -- Bernhard H. Mayer , QNET 's Swiss luxury brand, is proud to launch a new timepiece under its Mecanique Collection , the watchmaker's range of prestigious and distinct self-winding watches.
  • Each Mecanique watch is remarkable in design, style, and mechanics.
  • It also brandishes a more prominent watch face that fits seamlessly with the confident, sophisticated Mecanique look, making it the perfect dress watch to show off.
  • Bernhard H. Mayer® is part of the Federation of the Swiss Watch Industry (FH) to ensure all timepieces are made according to the Gold Standard of the watchmaking industry.

Telehealth Utilization Declined 76 Percent Nationally from 2020 to 2021

Retrieved on: 
Wednesday, March 29, 2023
Policy, COVID-19, Radiology, Pathology, FH, Medicine, FAIR, Patient, E&M, ERS, Growth, Hospital, Abdominal ultrasonography, Female, Online shopping, Nursing, Birth control, Health care

NEW YORK, March 29, 2023 /PRNewswire/ -- From 2020 to 2021, telehealth utilization declined 76 percent nationally while, during that same period, retail clinic utilization increased 51 percent nationally.1 Retail clinic growth had the greatest increase among all alternative places of service studied—retail clinics, urgent care centers, telehealth and ambulatory surgery centers (ASCs)—as well as emergency rooms (ERs), in a new FAIR Health white paper containing the sixth annual edition of FH® Healthcare Indicators and FH® Medical Price Index. Like the previous editions, this year's edition of FH Healthcare Indicators and FH Medical Price Index is intended to provide clarity to all healthcare stakeholders in a rapidly changing healthcare environment.

Key Points: 
  • Focusing on alternative places of service and ERs, FH Healthcare Indicators evaluate changes in utilization, geographic and demographic factors, diagnoses, procedures and costs.
  • Among the other key findings:
    From 2020 to 2021, utilization increased 14 percent in urgent care centers, while decreasing 7 percent in ASCs and 15 percent in ERs.
  • Despite its decline from 2020 to 2021, national telehealth utilization grew 5,017 percent nationally from 2016 to 2021.
  • Among the alternative places of service studied (retail clinics, urgent care centers, telehealth and ASCs), as well as ERs, telehealth held the highest percentage of medical claim lines in 2021, with 3.7 percent of all medical claim lines nationally.

FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol

Retrieved on: 
Wednesday, March 22, 2023
Insurance, Priority review, Life, Diarrhea, Genetics, Regeneron Pharmaceuticals, Aes, COVID-19, Fear, Automotive Supplier Innovation Program, FH, ANGPTL3, Apolipoprotein, Research, Sore throat, Cough, Vomiting, Rhinitis, Hypercholesterolemia, Genetic disorder, Patient, Physician, Risk, Common, Frustration, Disease, Diagnosis, Ageing, Mortality, FDA, Fever, Headache, MPH, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Fatigue, Pharmaceutical industry, Dietary supplement, Evinacumab

TARRYTOWN, N.Y., March 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for children as young as 5 years old to control dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH. Evkeeza was initially approved as an adjunct to other lipid-lowering therapies in those aged 12 years and older with HoFH in February 2021.

Key Points: 
  • Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for children as young as 5 years old to control dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH.
  • With this FDA approval, the HoFH community now has a much-needed treatment for young children, potentially making it possible for many to achieve recommended LDL-C levels much earlier in the course of this rare disease.
  • “Guidelines recommend screening all children at high risk for homozygous familial hypercholesterolemia starting at age 2.
  • Significant reductions were also observed in other key secondary endpoints including levels of apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C) and total cholesterol.

FAIR Health Initiative Illuminates Need for Cost Information in Shared Decision Making for Older Adults

Retrieved on: 
Wednesday, February 22, 2023
Organization, Caregiver, Health, FH, Patient, John A. Hartford Foundation, Depression, Ageing, Appetite, Prostate cancer, Spinal stenosis, EBSCO, Dark Ages, FAIR, Health care, Knowledge, Social, Heart failure, Social media, Nursing, Residential care

NEW YORK, Feb. 22, 2023 /PRNewswire/ -- An initiative undertaken by FAIR Health—a national, independent nonprofit organization dedicated to bringing transparency to healthcare costs—revealed the need for cost information in shared decision-making discussions for adults aged 65 and over with serious health conditions. Shared decision making is the discussion between patient and/or caregiver and healthcare provider, balancing clinical options and patient preferences and values to make healthcare decisions. The initiative, generously funded by The John A. Hartford Foundation, offered actionable insights regarding the challenges older adults face when making healthcare decisions and tools with cost information to help facilitate shared decision making among older adults, family caregivers and care partners. These insights and more are included in a brief released today by FAIR Health, Advancing Shared Decision Making among Older Adults with Serious Health Conditions: Lessons from FAIR Health's Grant-Funded Initiative.

Key Points: 
  • The initiative, generously funded by The John A. Hartford Foundation, offered actionable insights regarding the challenges older adults face when making healthcare decisions and tools with cost information to help facilitate shared decision making among older adults, family caregivers and care partners.
  • These insights and more are included in a brief released today by FAIR Health, Advancing Shared Decision Making among Older Adults with Serious Health Conditions: Lessons from FAIR Health's Grant-Funded Initiative .
  • To offer these tools in an easy-to-access, centralized location for older patients and family caregivers, FAIR Health developed a dedicated Older Adults section for its free, award-winning website FAIR Health Consumer ( fairhealthconsumer.org ).
  • There is a demonstrated appetite among older adults and family caregivers for cost information and resources to make healthcare decisions.

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

Retrieved on: 
Monday, January 9, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, IND, Cardiovascular disease, Non-Hodgkin lymphoma, PHH, Lilly, University, Kidney disease, Tissue, Primate, OTC, HBV, CMC, Duchenne muscular dystrophy, Trial of the century, Vivo, Novartis, LNP, Safety, Degenerative disease, FDA, Data, Gene editing, Hepatitis B virus, Completeness, Partnership, Stem cell, DMD, CAR, Hepatocyte, Patient, Mouse, Chromosomal translocation, NHL, Precision, CTA, PH1, FH, Sickle cell disease, Infant, Pharmaceutical industry, Risk management, Vaccine, Antibiotics

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.

Key Points: 
  • Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.
  • “In 2022, we advanced our corporate priorities strengthening the company and made significant progress with our clinical programs and research pipeline.
  • Progress azer-cel to decision point for Phase 2 trial in non-Hodgkin lymphoma (NHL) subjects who have relapsed following autologous CAR T treatment.
  • Present CAR T clinical update in the first quarter of 2023, based on patient accrual and follow-up.

Bosch Tools Names Robert Hesse as New President and CEO of North America

Retrieved on: 
Thursday, January 5, 2023
Dremel, Innovation, International trade, FH, 18V, Senior, Mind, International, Management

MOUNT PROSPECT, Ill., Jan. 5, 2023 /PRNewswire/ -- The Robert Bosch Tool Corporation named Robert Hesse as President and CEO of North America, effective November 1. In this position, Hesse will be responsible for the Robert Bosch Tool Corporation portfolio of businesses in North America which includes Bosch Power Tools and Accessories, Measuring Tools, Dremel Rotary Tools, and RotoZip Brands. Hesse will serve in this role after more than 25 years with Bosch, where he has held positions leading Bosch Communications Systems and, most recently, as the Senior Vice President of Sales at Bosch Accessories Group, a division of the Robert Bosch Tool Corporation.

Key Points: 
  • After Starting His Career with Bosch 27 Years Ago, Hesse Will Lead the Power Tools Division with Innovation and User Experience Top of Mind
    MOUNT PROSPECT, Ill., Jan. 5, 2023 /PRNewswire/ -- The Robert Bosch Tool Corporation named Robert Hesse as President and CEO of North America, effective November 1.
  • In this position, Hesse will be responsible for the Robert Bosch Tool Corporation portfolio of businesses in North America which includes Bosch Power Tools and Accessories, Measuring Tools, Dremel Rotary Tools, and RotoZip Brands.
  • Hesse will serve in this role after more than 25 years with Bosch, where he has held positions leading Bosch Communications Systems and, most recently, as the Senior Vice President of Sales at Bosch Accessories Group, a division of the Robert Bosch Tool Corporation.
  • Hesse looks forward to leading the Bosch Power Tools team as the company continues to push the broader tools industry towards a more innovative future.

EQS-News: Management handover at M+M Software SE

Retrieved on: 
Sunday, December 18, 2022
Executive Office of the President of the United States, Dassault Group, MUM, VAR, Weßling, Nemetschek, M+M, CFO, ISIN, News, Education, CAD, FH, CAM, CAD/CAM, BIM, CAE, Security (finance), Construction, Management, Autodesk

Wessling, December 14, 2022 – Mensch und Maschine Software SE (MUM - ISIN DE0006580806), a CAD/CAM/BIM specialist company, as of Jan 1, 2023 will complete the ongoing handover to the next management generation.

Key Points: 
  • Wessling, December 14, 2022 – Mensch und Maschine Software SE (MUM - ISIN DE0006580806), a CAD/CAM/BIM specialist company, as of Jan 1, 2023 will complete the ongoing handover to the next management generation.
  • Currently, beside CFO Markus Pech from M+M SE, Volker Nesenhoener (CAD/CAM Software) and Marcus Hoellrich (VAR Europe) represent the two M+M segments, while Rainer Sailer (Architecture/BIM) and Wolfgang Huber (Manufacturing/CAE) are representing their industries across segments.
  • In addition, other members of the upper management levels take part in the regular board meetings as required.
  • In 2003 he started in the finance department at M+M, since 2016 responsible for group finances and administration as CFO and Managing Director of Mensch und Maschine Software SE.

Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

Retrieved on: 
Wednesday, November 30, 2022
Part, Food, Risk, Disease, FH, Ageing, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Priority, FDA, Priority review, Pharmaceutical industry, Evinacumab

TARRYTOWN, N.Y., Nov. 30, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023.

Key Points: 
  • HoFH is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is the most severe form of familial hypercholesterolemia (FH).
  • The sBLA is supported by data from a three-part trial evaluating Evkeeza in children aged 5 to 11 years with HoFH.
  • The trial met its primary endpoint, showing children who added Evkeeza to other lipid-lowering therapies reduced their LDL-C by 48% at week 24 on average.
  • Part A (n=6) was a Phase 1b trial designed to assess the pharmacokinetics (PK), safety and tolerability of Evkeeza.

Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition

Retrieved on: 
Tuesday, November 29, 2022
General Health, Hospitals, Health, Cardiology, Managed Care, Diagnosis, Stroke, Emory University School of Medicine, Mutation, Gene, Cardiovascular disease, Risk, Patient, Flag, Emory Healthcare, Emory Center for Alternative Investments, MD, Health information management, Cholesterol, FH, Research, Department of Medicine – University of Pamplona, Infarction, Apolipoprotein, Pharmaceutical industry, Medicine

Although its one of the most common genetic causes of early heart attacks and premature coronary heart disease, FH is dramatically underdiagnosed in patients.

Key Points: 
  • Although its one of the most common genetic causes of early heart attacks and premature coronary heart disease, FH is dramatically underdiagnosed in patients.
  • Without proper treatment, impacted individuals have up to a 20-fold increased risk of a heart attack or development of premature coronary artery disease.
  • As part of the new collaborative project, Emory Heart & Vascular Center will use the Family Heart Foundations innovative machine-learning technology, FIND FH , to identify and screen individuals at risk.
  • As a result of this mutation, cholesterol is not adequately cleared, leading to high levels of low-density lipoprotein cholesterol (LDL-C) or bad cholesterol in the bloodstream.